RxDoctor Payments DataLook up a doctor →

Darryle Bullard, MD

Pulmonary Disease · Cullman, ALNPI 1245288653

Payments from drug & device makers

$380,036in general payments, 2019–2025

Across 451 payments — averaging $842.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corvista Health, Inc.$350K
  • Verona Pharma, Inc.$22K
  • GSK$2K
  • AstraZeneca$2K
  • Insmed, Inc.$462
  • Grifols USA, LLC$435
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$20,06667%
  • Travel & lodging$5032%
  • Food & beverage$8,87030%
  • Education$5962%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$380,036 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$172,854
Medicare patients
310
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter428$388,610
Breztri AerosphereBudesonide/Glycopyr/Formoterol227$210,356
Spiriva RespimatTiotropium Bromide36$31,784
Breo ElliptaFluticasone/Vilanterol30$16,534
Varenicline Tartrate52$12,103
Albuterol Sulfate HfaAlbuterol Sulfate263$11,882
Azelastine Hcl182$8,829
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,308
Roflumilast106$7,905
Ipratropium Bromide73$3,891
Fluticasone Propionate144$3,118
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,951
Levalbuterol Tartrate HfaLevalbuterol Tartrate24$2,509
Mometasone Furoate14$2,481
Azithromycin128$2,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$2,026$413,452472 claims
AstraZenecaBreztri Aerosphere$1,812$210,356227 claims
Boehringer IngelheimSpiriva Respimat$360$31,78436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →